SLC16A3 and urinary bladder cancer: Furthermore, the combination of MCT4 IHC and previously identified noninvasive peripheral blood biomarkers, such as survivin, circulating tumor cells, and systemic combining inflammatory score, may also help to further improve the clinical management of bladder cancer (38–41).